SALT LAKE CITY, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued a third patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) assay to market.  U.S. patent no. 12,104,212, entitled “Personalized Methods for Detecting Circulating Tumor DNA,” demonstrates Myriad’s continued efforts to advance ...